Recent research have focused on the convergence of glucagon-like peptide-1|GIP|GCGR agonist therapies and dopamine signaling. While GIP stimulators are commonly employed for addressing type 2 T2DM, their unexpected consequences on reinforcement circuits, specifically mediated by dopaminergic networks, are gaining substantial focus. This report prov